AtriCure, Inc. (NASDAQ:ATRC – Get Free Report)’s stock price reached a new 52-week high during trading on Wednesday after the company announced better than expected quarterly earnings. The stock traded as high as $63.79 and last traded at $63.1830, with a volume of 90,550 shares traded. The stock had previously closed at $60.41.
The medical device company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.23. The company had revenue of $154.45 million for the quarter, compared to analysts’ expectations of $151.05 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.
Trending Headlines about AtriCure
Here are the key news stories impacting AtriCure this week:
- Positive Sentiment: AtriCure reported third-quarter adjusted earnings of $0.17 per share and revenue of $154.45 million, ahead of analyst estimates of $151.05 million in revenue. Benzinga: AtriCure analysts boost their forecasts
- Positive Sentiment: Needham raised its price target from $64 to $70 and maintained a Buy rating; BTIG also raised its target to $70, reflecting more favorable analyst expectations after the results. StreetInsider: BTIG raises AtriCure price target
- Positive Sentiment: The company projects 2026 adjusted EBITDA of $91 million to $94 million and is targeting completion of BoxX-NoAF trial enrollment by year-end, offering an earnings outlook and clinical milestone for investors to track. Seeking Alpha: AtriCure’s 2026 EBITDA outlook and trial enrollment target
- Neutral Sentiment: AtriCure expects 2026 revenue of $606 million to $610 million, broadly around the cited FactSet estimate of $606.2 million. MarketScreener: AtriCure’s 2026 revenue outlook
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the stock. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 24th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Wednesday, October 21st. Citizens Jmp upped their price objective on AtriCure from $52.00 to $68.00 and gave the company a “market outperform” rating in a research note on Wednesday, October 21st. UBS Group cut AtriCure from a “buy” rating to a “sell” rating in a research report on Wednesday, October 21st. Finally, Piper Sandler lifted their target price on AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 27th. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, AtriCure presently has an average rating of “Hold” and an average price target of $57.00.
Check Out Our Latest Analysis on ATRC
Insider Activity
In related news, insider Karl S. Dahlquist sold 9,370 shares of the company’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $48.89, for a total value of $458,099.30. Following the transaction, the insider owned 87,319 shares in the company, valued at approximately $4,269,025.91. This represents a 9.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Regina E. Groves sold 5,313 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $54.22, for a total transaction of $288,070.86. Following the sale, the director owned 34,546 shares of the company’s stock, valued at $1,873,084.12. This trade represents a 13.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 30,622 shares of company stock valued at $1,626,003 over the last ninety days. 4.00% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On AtriCure
Large investors have recently made changes to their positions in the company. Brighton Jones LLC bought a new stake in AtriCure in the 3rd quarter valued at $279,000. Ethic Inc. bought a new position in AtriCure during the 3rd quarter worth $203,000. Provenance Wealth Advisors LLC bought a new position in AtriCure during the 3rd quarter worth $217,000. Oregon Public Employees Retirement Fund acquired a new stake in shares of AtriCure during the third quarter worth $641,000. Finally, ProShare Advisors LLC acquired a new stake in shares of AtriCure during the third quarter worth $385,000. Institutional investors own 99.11% of the company’s stock.
AtriCure Stock Performance
The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The stock’s 50-day moving average price is $56.03 and its 200-day moving average price is $38.40. The company has a market cap of $3.23 billion, a P/E ratio of 302.38 and a beta of 1.23.
AtriCure Company Profile
AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.
The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.
Read More
- Five stocks we like better than AtriCure
- High Voltage Returns: Talen Energy Powers the Data Center Rush
- 3 Dividend Increases Above 10%, But Which Offers the Most Income?
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
